Leica Biosystems PD-L1 BOND antibody

Wednesday, 05 December, 2018 | Supplied by: Leica Microsystems Pty Ltd

Leica Biosystems’ PD-L1 BOND antibody is designed for use on the company’s fully automated BOND IHC and ISH staining platform.

The PD-L1 (programmed death - ligand 1) antibody uses the MKP1A07310 (clone 73-10) expressed by Abcam on behalf of Merck KGaA, which owns all IP rights to this antibody. It joins the ALK (anaplastic lymphoma kinase) antibody as the latest addition to Novocastra’s growing lung menu of primary antibodies.

Leica Biosystems has optimised these two clones into a ready-to-use format for use on the BOND IHC and ISH staining platform. This allows labs to perform ALK and PD-L1 testing on the BOND system with rapid turnaround times, reliable staining and walk-away convenience.

Online: www.leica-microsystems.com
Phone: 1800 625 286

Content from other channels on our network

Business must continue to lead on addressing climate change

CSIRO projection sees 4000 new jobs in HEM sector

Novel approach to desalination tech could help to ease water scarcity

Heavy mine site electric vehicles to get supercharged

Sydney Water trial at Cascade Water Filtration Plant reduces PFAS levels

Artificial 'nose' can sniff out damaged fruit and spoiled meat

Leading fresh produce industry advocates join IFPA ANZ board

Meat alternatives preferred if much cheaper than the real thing

Keeping it cool for Spanish soup making

Genetic predisposition plays role in bitter coffee taste

Manufacturing production returns to expansion: S&P Global

Filling the logic solver gap

Orica eliminates one million tonnes of GHG emissions

IO-Link and the role of the IO-Link Master

Fortescue endorses global movement for a fossil fuel treaty

Leica Biosystems PD-L1 BOND antibody

Cayman Chemical Natural Products Screening Library

AdipoGen Life Sciences DYRK inhibitors

GroPep Bioreagents IGF-1 Family Proteins

Content from other channels on our network